Abstract：Objective: To investigate the effect of somatostatin combined with lansoprazole on serum gastrin, inflammatory factors and adverse reactions in patients with peptic ulcer (PU). Methods: 126 patients with PU in the hospital were selected as the subjects by simple random sampling method, and they were randomly divided into the control group and the observation group, 63 cases in each group. All patients were given basic treatments after admission. On the basis, the control group was treated with lansoprazole while the observation group was treated with somatostatin combined with lansoprazole. After 48h of medication, serum gastrin, motilin, somatostatin and other gastrointestinal hormones were compared between the two groups before and after treatment. The inflammatory factor, epidermal growth factor (EGF) and transforming growth factor alpha (TGF-ɑ) were detected, and adverse reactions in the two groups were statistically analyzed. Results: After treatment, levels of gastrin, motilin and somatostatin in the two groups were significantly lower than those before treatment, and the levels in the control group [(86.5±12.7) μmol/L, (208.4±31.2) pg/mL, (35.2±5.2) pg/mL] were significantly higher than those in the observation group [(71.3±10.6) μmol/L, (152.6±23.4) pg/mL, (27.9±4.1) pg/mL] (P<0.05). After treatment, inflammatory factors CRP and IL-6 in the two groups were decreased significantly, without significant difference between groups (P>0.05). Levels of EGF and TGF-ɑ in the two groups were significantly higher than those before treatment, and the levels in control group [(0.62±0.13) pg/mL, (2.45±0.47) pg/mL] were significantly lower than those in the observation group [(0.84±0.15) pg/mL, (2.63±0.51) pg/mL] (P<0.05). The total response rate of the control group was significantly lower than that of the observation group (66.7% vs 82.5%) (P<0.05), but there was no significant difference in the total incidence of adverse reactions between the two groups (15.9% vs 7.9%) (P>0.05). Conclusion: Somatostatin combined with lansoprazole can effectively relieve clinical symptoms of PU and promote the recovery of gastrointestinal function, without increasing adverse reactions and with high safety.
李京, 王东旭, 朱宏斌, 刘秋菊. 生长抑素联合兰索拉唑治疗对消化性溃疡患者血清胃泌素炎症因子及不良反应的影响[J]. 河北医学, 2019, 25(10): 1638-1641.
LI Jing, WANG Dongxu, ZHU Hongbin, et al. Effect of Somatostatin combined with Lansoprazole on Serum Gastrin, Inflammatory Factors and Adverse Reactions in Patients with Peptic Ulcer. HeBei Med, 2019, 25(10): 1638-1641.
2019, Vol. 25 
冀公网安备13080202000677号